Shareholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2021 |
Dec. 31, 2020 |
|
Schedule of stock-based compensation expense [Abstract] | ||
Research and development options expense | $ 304,421 | $ 252,173 |
Total research and development expenses | 304,421 | 252,173 |
General and administrative options expense | 1,955,096 | 1,168,281 |
Stock and warrants issued to consultants and employees | 1,980,900 | 710,792 |
Total general and administrative expenses | 3,935,996 | 1,879,073 |
Total stock-based compensation expense | $ 4,240,417 | $ 2,131,246 |
X | ||||||||||
- Definition General and administrative options and warrants expense. . No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Stock issued to consultants and employees. . No definition available.
|
X | ||||||||||
- Definition The amount of stock-based compensation expense. No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|